DGAP-News: STRATEC Biomedical AG / Key word(s): AGM/EGM/Dividend STRATEC Annual General Meeting approves record dividend 09.06.2016 / 16:24 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- STRATEC Annual General Meeting approves record dividend Birkenfeld, June 9, 2016 At the Annual General Meeting of STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) held today in Pforzheim, the company's shareholders approved the distribution of a dividend of EUR 0.75 per share for the 2015 financial year (previous year: EUR 0.70 per share). This is the twelfth consecutive increase in the dividend since payment of the first dividend in 2004. The distribution total amounts to EUR 8.9 million and represents the highest dividend payment made in STRATEC's history to date. The dividend will be paid out to shareholders via their depositary banks on June 10, 2016. Furthermore, shareholders approved the actions of the Board of Management and the Supervisory Board. Shareholders also approved the other proposals submitted by the management with large majorities. They thus endorsed the proposal made by the Supervisory Board to elect Ebner Stolz GmbH & Co. KG Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft, Stuttgart, as auditors of STRATEC Biomedical AG for the 2016 financial year. Furthermore, the shareholders approved an intercompany agreement. Around 72 % of the company's share capital was represented at the Annual General Meeting. Further information about our Annual General Meeting can be found on the company's website at www.stratec.com/agm, where details of voting results have also been published. About STRATEC STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange. Further information can be obtained from: STRATEC Biomedical AG André Loy, Corporate Communications Gewerbestr. 37, 75217 Birkenfeld Germany Tel: +49 7082 7916-190 Fax: +49 7082 7916-999 [email protected] www.stratec.com --------------------------------------------------------------------------- 09.06.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: STRATEC Biomedical AG Gewerbestr. 37 75217 Birkenfeld Germany Phone: +49 (0)7082 7916 0 Fax: +49 (0)7082 7916 999 E-mail: [email protected] Internet: www.stratec.com ISIN: DE000STRA555 WKN: STRA55 Indices: TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Terminbörse EUREX End of News DGAP News Service --------------------------------------------------------------------------- 470605 09.06.2016